Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment;Estado clínico, adherencia al TARGA y calidad de vida en pacientes con infección por el VIH tratados con antirretrovirales

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 10, 2005, Pages 581-585

  Ruiz Pérez, Isabel ^a   De Labry Lima, Antonio Olry ^a   López Ruz, Miguel Ángel ^b   Del Arco Jiménez, Alfonso ^c   Rodríguez Baño, Jesús ^d   Causse Prados, Manuel ^e   Pasquau Liaño, Juan ^b   Martín Rico, Patricia ^e   Prada Pardal, José Luis ^c   De La Torre Lima, Javier ^c   López Gómez, Manuel ^b   Marcos, Miguel ^c   Muñoz, Nuria ^e   Morales, Dolores ^d   Muñoz, Isabel ^e  

^a ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL COSTA DEL SOL   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Antiretroviral therapy; Highly active; HIV; Quality of life

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUSTRALIA; COGNITION; DISEASE COURSE; FEMALE; HEALTH PRACTITIONER; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PARAMETER; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SPAIN; STATISTICAL SIGNIFICANCE; SURVIVAL; VIRUS LOAD;

EID: 29444440833     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13081565     Document Type: Article

References (32)

1. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170:229-38.
2. Alonso MM, Gómez JL, Santolaria F, Rodríguez F, Essardas H, Rodríguez E, et al. Eficacia del tratamiento antirretroviral en pacientes con infección por el virus de la inmunodeficiencia humana. Estudio de 807 pacientes. Med Clin (Barc). 2000;115:481-6.
3. Badía X, Del Llano J. Investigación de resultados en salud. Med Clin (Barc). 2000;114 Supl 3:1-7.
4. Shumaker S, Naughton M. The International Assessment of Health-Related Quality of Life: A theoretical pespective. En: Shumaker S, Berzon R, editors. The International Assessment of Health-related Quality of life: Theory, Traslation, Measurement and Analysis. Oxford: Rapid Communications; 1995.
5. Wu AW, Lamping DL. Assessment of quality in HIV disease. AIDS. 1994;8:S349-S59.
6. Martínez González J, García Ordóñez MA, Sãnchez Simonet MV, Juãrez Fernãndez C. Infecciõn por VIH, calidad de vida e inhibidores de la proteasa. Med Clin (Barc). 2000;114:196.
7. Badĩa X, Guerra L, Garcĩa M, Podzamczer D. La evaluaciõn de la calidad de vida en los pacientes con infección por el VIH y SIDA. Med Clin (Barc). 1999;112:739-44.
8. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patients outcomes. JAMA. 1997;278:47-50.
9. Kotler DP. Management of nutritional alterations and issues concerning quality of life. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16 Suppl 1:30-5.
10. Cunningham WE, Shapiro MF, Hays RD, Dixon WJ, Visscher BR, George WL, et al. Constitutional Symptoms and Health-related Quality of Life in Patients with Symptomatic HIV Disease. Am J Med. 1998;104:129-36.
11. Blanch J, Martínez E, Rousaud A, Blanco JL, García-Viejo MA, Peri JM, et al. Preliminary data of prospective study on neuropsychiatric side effect after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001;27:336-43.
12. Swindells S, Mohr J, Justis JC, Berman S, Sequier C, Wagener MM, et al. Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness. Int J STD AIDS. 1999;10:383-391.
13. Badía X, Podzamczer D, García M, López-Lavid C, Consiglio E. A randomized study comparing instruments for measuring Health-Related Quality of Life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. AIDS. 1999;13:1727-35.
14. Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zubkoff M, et al. The Medical outcome Study. An application of methods for monitoring the results of medical care. JAMA. 1989;262:925-30.
15. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481-93.
16. Badía X, Podzamczer D, López-Lavid C, García M. Medicina basada en la evidencia y la validación de cuestionarios de calidad de vida; La versión española infectadosdel MOS-HPV para la evaluación de la calidad de vida en pacientes infectados por el VIH. Enferm Infecc Microbiol Clin. 1999;17 Supl 2:103-13.
17. CDC. 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1-20.
18. Marmot M. Multilevel approaches to understanding social determinants. En: Berkman L, Kawachi I, editors. Social epidemiology. United States of America. Oxford University Press; 2000.
19. Campsmith ML, Nakashima AK, Davidson AJ. Self-reported health-related quality of life in persons with HIV infection: results from multi-site interview Project. Health Qual Outcomes. 2003;1:12-8.
20. Revicki DA, Moyle G, Stellbrink HJ, Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) study group. AIDS. 1999;13:851-8.
21. Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA. Relationship between CD4 counts, viral burden and quality of life over time in HIV-1-infected patients. Med Car. 2000;38:404-10.
22. Murri R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, et al. Determinants of health-related quality of life in HIV-infected patients. AIDS Care. 2003;15:581-90.
23. García Ordóñez MA, Mansilla JJ, Nieto E, Careto MR, Salas F, Vallejo M. Calidad de vida relacionada con la salud de pacientes infectados por el VIH medida por el Cuestionario de Salud SF-36. An Med Interna. 2001;18:74-9.
24. Hays R, Cunningham W, Cathy S, Ira W, Wu A, Cleary P. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV cost and services utilization study. Am J Med. 2000;108:714-22.
25. Bing EG, Hays RD, Jacobson LP, Chen B, Gange SJ, Kass NE, et al. Health-related quality of life among people with HIV disease: results from the multicenter AIDS cohort study. Qual Life Res. 2000;9:55-63.
26. Nunes JA, Raymond SF, Nicholas PK, D'Meza Leuner J, Webster A. Social support, quality of life in HIV/AIDS. AIDS Care. 1996;8:15-31.
27. Call SA, Klapow JC, Stewart KE, Westfall AO, Mallinger AP, DeMasi RA, et al. Health-related quality of life and virologic oucomes in an HIV clinic. Qual Life Res. 2000;9:977-85.
28. Gill CJ, Griffith JL, Jacobson D, Skinner S, Gorbach SL, Wilson IB. Relationship of HIV viral load, CD4 counts, and HAART use to health-related quality of life. J Acquir Immune Defic Syndr. 2002;30:485-92.
29. Nieuwkerk PT, Gisolf EH, Reijers MH, Lange JM, Danner SA, Sprangers MA, et al. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS. 2001;15:1985-91.
30. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advance HIV disease. Advance HIV Disease Ritonavir Study Group. AIDS. 1998;12:1495-502.
31. Fumaz CR, Tuldrá A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-53.
32. Low-Beer S, Chan K, Wood E, Yip B, Montaner J, O'Shaughnessy M, et al. Health related quality of life among persons with HIV after the use of protease inhibitor. Qual Life Res. 2000;9:941-9.